Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Inhaled Epinephrine (DMC-IH1) in Healthy Volunteers
NCT06013150Phase 1Completed
- Sponsor
- De Motu Cordis
- Start
- Oct 2023
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of epinephrine in anaphylaxis (3 arms), sponsored by De Motu Cordis. Primary endpoints: Number of participants with adverse events (AEs) up to 7 days, Number of participants with clinical laboratory abnormalities up to 7 days and 2 more. Started Oct 2023; status: completed.
02
Drugs
epinephrine
03
Conditions
anaphylaxis
Beyond the preview
Go deeper on NCT06013150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06013150.